Cited by 2,575Multiple Myeloma Research and TreatmentsBone health and treatmentsChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Open access

Singhal, Seema, Mehta, Jayesh, Desikan, Raman, Ayers, Dan, Roberson, Paula, Eddlemon, Paul, Munshi, Nikhil, Anaissie, Elias, Wilson, Carla, Dhodapkar, Madhav, Zeldis, Jerome, Siegel, David, Crowley, John, Barlogie, Bart·1999·New England Journal of Medicine

DOI 10.1056/nejm199911183412102

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease. METHODS: Eighty-four previously treated patients with refractory myeloma (76 with a relapse after high-dose chemotherapy) received oral thalidomide as a single agent for a median of 80 days (range, 2 to 465). The starting dose was 200 mg daily, and the dose was increased by 200 mg every two weeks until it reached 800 mg per day. Response was assessed on the basis of a reduction of the myeloma protein in serum or Bence Jones protein in urine that lasted for at least six weeks. RESULTS: The serum or urine levels of paraprotein were reduced by at least 90 percent in eight patients (two had a complete remission), at least 75 percent in six patients, at least 50 percent in seven patients, and at least 25 percent in six patients, for a total rate of response of 32 percent. Reductions in the paraprotein levels were apparent within two months in 78 percent of the patients with a response and were associated with decreased numbers of plasma cells in bone marrow and increased hemoglobin levels. The microvascular density of bone marrow did not change significantly in patients with a response. At least one third of the patients had mild or moderate constipation, weakness or fatigue, or somnolence. More severe adverse effects were infrequent (occurring in less than 10 percent of patients), and hematologic effects were rare. As of the most recent follow-up, 36 patients had died (30 with no response and 6 with a response). After 12 months of follow-up, Kaplan-Meier estimates of the mean (+/-SE) rates of event-free survival and overall survival for all patients were 22+/-5 percent and 58+/-5 percent, respectively. CONCLUSIONS: Thalidomide is active against advanced myeloma. It can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy.

Integrity signals

Registry

Crossref · 10.1056/nejm199911183412102

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Bone marrow transplant
Szer, J. (1999) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,373
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Unbalanced repeated-measures models with structured covariance matrices.
Jennrich, R., & Schluchter, M. (1986) · Biometrics · doi:10.2307/2530695 · Cited by 1,382
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191

Show all 35 references

Research works printed but not linked: 10

Barlogie B, 1997, Clin Cancer Res, 3, 2605
Singhal S, 1996, Blood, 88, 611a
Munshi N, 1998, Blood, 92, 98a
10.2307/2281868 · DOI · Paper page
Mantel N, 1966, Cancer Chemother Rep, 50, 163
Figg WD, 1997, Proc Am Soc Clin Oncol, 16, 333a
Fine HA, 1997, Proc Am Soc Clin Oncol, 16, 385a
Long G, 1998, Proc Am Soc Clin Oncol, 17, 181a
Eisen T, 1998, Proc Am Soc Clin Oncol, 17, 441a
Nguyen M, 1997, Int J Oncol, 10, 965

Sorted by citations

Items 601–700 of 1,002

Trial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 61
Multidisciplinary Management of Primary Tumors of the Vertebral Column
Hsu, W., Kosztowski, T. A., Zaidi, H. A., Dorsi, M. J., Gokaslan, Z. L., & Wolinsky, J. (2009) · Current Treatment Options in Oncology · doi:10.1007/s11864-009-0102-8 · Cited by 60
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma
Wanchoo, R., Abudayyeh, A., Doshi, M. D., Edeani, A., Glezerman, I. G., Monga, D., Rosner, M. H., & Jhaveri, K. D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06100616 · Cited by 61
Therapeutic renaissance of thalidomide in the treatment of haematological malignancies
Ribatti, D., & Vacca, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403852 · Cited by 60
Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple Myeloma
Avigdor, A., Raanani, P., Levi, I., Hardan, I., & Ben‐Bassat, I. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109099330 · Cited by 60
Amyloid deposition in the oral cavity: A retrospective study and review of the literature
Stoopler, E. T., Sollecito, T. P., & Chen, S. (2003) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1067/moe.2003.136 · Cited by 60
Amyloidosis
Khan, M. F., & Falk, R. H. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.913.686 · Cited by 59
Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia
Mesa, R. A., Hanson, C. A., Li, C., Yoon, S., Rajkumar, S. V., Schroeder, G. S., & Tefferi, A. (2002) · Blood · doi:10.1182/blood.v99.11.4131 · Cited by 60
Pharmacology of antineoplastic agents in older cancer patients.
Lichtman, S. M., & Skirvin, J. A. (2000) · PubMed · Cited by 60
Multiple Myeloma
Anderson, K. C., Shaughnessy, J. D., Barlogie, B., Harousseau, J., & Roodman, G. D. (2002) · Hematology · doi:10.1182/asheducation-2002.1.214 · Cited by 61
Self-citation
Drug repurposing: Clinical practices and regulatory pathways
Saranraj, K., & Kiran, P. U. (2024) · Perspectives in Clinical Research · doi:10.4103/picr.picr_70_24 · Cited by 66
Drug-Induced Thrombosis: An Update
Ramot, Y., Nyska, A., & Spectre, G. (2013) · Drug Safety · doi:10.1007/s40264-013-0054-6 · Cited by 59
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression‐free survival in multiple myeloma
Maiolino, Â., Hungria, V., Garnica, M., Oliveira-Duarte, G. B., de Oliveira, L. C. O., Mercante, D., MIRANDA, E. C. M., Quero, A. A., Peres, A. L., Barros, J. C., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23274 · Cited by 59
Emerging therapies for multiple myeloma
Podar, K., Tai, Y., Hideshima, T., Vallet, S., Richardson, P. G. G., & Anderson, K. C. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802676278 · Cited by 59
Serendipity in Cancer Drug Discovery: Rational or Coincidence?
Prasad, S., Gupta, S. C., & Aggarwal, B. B. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.03.004 · Cited by 59
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance
Hogan, J. J., & Weiss, B. M. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03160316 · Cited by 62
Chemotherapy in the elderly
Lichtman, S. M. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.027 · Cited by 59
The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets
Abramson, H. N. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.015 · Cited by 58
Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies
Pellacani, C., & Eleftheriou, G. (2020) · Advances in Medical Sciences · doi:10.1016/j.advms.2020.04.001 · Cited by 60
Deciphering the mystery of thalidomide teratogenicity
Ito, T., & Handa, H. (2011) · Congenital Anomalies · doi:10.1111/j.1741-4520.2011.00351.x · Cited by 59
IL-6 and MYC collaborate in plasma cell tumor formation in mice.
Rutsch, S., Neppalli, V., Shin, D.-M., Dubois, W. D., Morse, H., Goldschmidt, H., & Janz, S. (2010) · Blood · doi:10.1182/blood-2009-08-237941 · Cited by 58
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
Palumbo, A., Avonto, I., Bruno, B., Ambrosini, M. T., Bringhen, S., Cavallo, F., Falco, P., & Boccadoro, M. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00610.x · Cited by 58
Is repositioning of drugs a viable alternative in the treatment of tuberculosis?
Palomino, J. C., & Martin, A. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks405 · Cited by 58
Repurposing Immunomodulatory Drugs to Combat Tuberculosis
Fatima, S., Bhaskar, A., & Dwivedi, V. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645485 · Cited by 58
Thalidomide: an old drug with new clinical applications
Laffitte, E., & Revuz, J. E. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.1.47 · Cited by 58
The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro
Cheung, W.-C., & Ness, B. V. (2001) · Leukemia · doi:10.1038/sj.leu.2402022 · Cited by 57
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study
Piccaluga, P. P., Visani, G., Sa, P., Ascani, S., Grafone, T., Isidori, A., Malagola, M., Finelli, C., Martinelli, G., Ricci, P., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402596 · Cited by 58
Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance
Pulè, M. A., Gulmann, C., Dennis, D., McMahon, C., Jeffers, M. D., & Smith, O. P. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03761.x · Cited by 58
Daratumumab granted breakthrough drug status
Laubach, J. P., Tai, Y., Richardson, P. G. G., & Anderson, K. C. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.889681 · Cited by 57
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Mi, D., Li, Y., Gu, H., Li, Y., & Chen, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115444 · Cited by 58
Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis
Koh, K.-R. (2004) · Blood · doi:10.1182/blood-2004-03-0828 · Cited by 57
Cereblon in health and disease
Kim, H. K., Ko, T. H., Nyamaa, B., Lee, S. R., Kim, N., Ko, K. S., Rhee, B. D., Park, C., Nilius, B., & Han, J. (2016) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-016-1854-1 · Cited by 55
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients
Bladé, J., Miguel, J. F. S., Fontanillas, M., Esteve, J., Maldonado, J., Alcalá, A., Brunet, S., García-Conde, J., Besalduch, J., Moro, M. J., et al. (2001) · The Hematology Journal · doi:10.1038/sj.thj.6200115 · Cited by 57
Multiple Myeloma: New Insights and Therapeutic Approaches
Anderson, K. C. (2000) · Hematology · doi:10.1182/asheducation-2000.1.147 · Cited by 57
The biological treatment of renal-cell carcinoma and melanoma
Nathan, P., & Eisen, T. G. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00650-2 · Cited by 58
Phase I study of oral lenalidomide in patients with refractory metastatic cancer
Dahut, W. L., Aragon‐Ching, J. B., Woo, S., Tohnya, T. M., Gulley, J. L., Arlen, P. M., Wright, J. J., Ventiz, J., & Figg, W. D. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009335001 · Cited by 56
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study
Schey, S., Morgan, G. J., Ramasamy, K., Hazel, B., Ładoń, D., Corderoy, S., Jenner, M. W., Phekoo, K. J., Boyd, K. D., & Davies, F. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08250.x · Cited by 55
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial
Kropff, M. H., Baylon, H. G., Hillengaß, J., Robak, T., Hájek, R., Liebisch, P., Goranova-Marinova, V. S., Hulin, C., Bladé, J., Caravita, T., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044271 · Cited by 56
Thalidomide protects endothelial cells from doxorubicin‐induced apoptosis but alters cell morphology
Kaushal, V., Kaushal, G. P., Melkaveri, S. N., & Mehta, P. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7933.2003.00573.x · Cited by 56
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth
Munguia, A., Ota, T., Miest, T. S., & Russell, S. J. (2008) · Gene Therapy · doi:10.1038/gt.2008.45 · Cited by 56
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
Bensinger, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6863 · Cited by 55
Three-Dimensional-Printed Bioceramic Scaffolds with Osteogenic Activity for Simultaneous Photo/Magnetothermal Therapy of Bone Tumors
Zhuang, H., Lin, R., Liu, Y., Zhang, M., Zhai, D., Huan, Z., & Wu, C. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01095 · Cited by 55
The role of the tumor microenvironment in hematological malignancies and implication for therapy
Zhou, J. (2005) · Frontiers in bioscience · doi:10.2741/1642 · Cited by 56
Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone
Coleman, M., Leonard, J. P., Lyons, L., Szelényi, H., & Niesvizky, R. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50044 · Cited by 56
Bone marrow angiogenesis in multiple myeloma: effect of therapy
Kumar, S. K., Fonseca, R., Dispenzieri, A. A., Lacy, M. Q., Lust, J. A., Witzig, T. E., Gertz, M. A., Kyle, R. A., Greipp, P. R., & Rajkumar, S. V. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03871.x · Cited by 56
Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone
Dimopoulos, M. A., Tsatalas, C., Zomas, A., Hamilos, G., Panayiotidis, P. G., Margaritis, D., Matsouka, C., Economopoulos, T., & Anagnostopoulos, N. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50079 · Cited by 56
Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon
Akuffo, A. A., Alontaga, A. Y., Metcalf, R. S., Beatty, M. S., Becker, A., McDaniel, J. M., Hesterberg, R. S., Goodheart, W. E., Gunawan, S., Ayaz, M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816868 · Cited by 55
Thalidomide in Low Doses is Effective for the Treatment of Resistant or Relapsed Multiple Myeloma and for Plasma Cell Leukaemia
Johnston, R. E., & Abdalla, S. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190290006143 · Cited by 55
Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature
Ginsburg, P. M., Dassopoulos, T., & Ehrenpreis, E. D. (2001) · Annals of Medicine · doi:10.3109/07853890108995961 · Cited by 55
The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells.
Pollmann, C. T., Huang, X., Mall, J. W., Bech‐Otschir, D., Naumann, M., & Dubiel, W. (2001) · PubMed · Cited by 55
Consolidation therapy of multiple myeloma withthalidomide–dexamethasone after intensive chemotherapy
Alexanian, R., Weber, D., Giralt, S. A., & Delasalle, K. B. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf188 · Cited by 55
Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma
Sezer, O., Vesole, D. H., Singhal, S., Richardson, P. G. G., Stadtmauer, E. A., Jakob, C., Boral, A. L., Esseltine, D.-L. W., & Mehta, J. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.064 · Cited by 54
Self-citation
NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies
Alyea, E. P., DeAngelo, D. J., Molldrem, J. J., Pagel, J. M., Przepiorka, D., Sadelin, M., Young, J. W., Giralt, S., Bishop, M., & Riddell, S. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.05.005 · Cited by 54
Bone marrow immunohistology of plasma cell neoplasms
Wei, A. H., & Juneja, S. (2003) · Journal of Clinical Pathology · doi:10.1136/jcp.56.6.406 · Cited by 54
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 61
Changing Paradigms in the Treatment of Malignant Pheochromocytoma
Grogan, R. H., Mitmaker, E. J., & Duh, Q. (2011) · Cancer Control · doi:10.1177/107327481101800205 · Cited by 54
Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside
Bruno, B., Giaccone, L., Rotta, M., Anderson, K. C., & Boccadoro, M. (2005) · Leukemia · doi:10.1038/sj.leu.2403905 · Cited by 57
Promising preclinical activity of 2-methoxyestradiol in multiple myeloma
Witzig, T. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.11011.x · Cited by 54
Cereblon binding molecules in multiple myeloma
Kortüm, K. M., Zhu, Y. X., Shi, C., Jedlowski, P. M., & Stewart, A. K. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.03.003 · Cited by 53
Cereblon negatively regulates TLR4 signaling through the attenuation of ubiquitination of TRAF6
Min, Y., Wi, S. M., Kang, J., Yang, T., Park, C., Park, S., Chung, S., Shim, J., Chun, E., & Lee, K. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.226 · Cited by 53
Multiple Myeloma
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A. A., Cohen, A. D., Devine, S. M., Djulbegović, B., Faber, E. A., Gasparetto, C., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0095 · Cited by 53
Self-citation
An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
Prince, H. M., Schenkel, B., & Mileshkin, L. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190601001904 · Cited by 53
Immunotherapeutic and antitumour potential of thalidomide analogues
Marriott, J. B., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.4.675 · Cited by 52
Advances in disease biology: Therapeutic implications
Anderson, K. C. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90088-5 · Cited by 53
Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology
Lythgoe, M. P., & Prasad, V. K. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01893-5 · Cited by 52
Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma
Baumann, P., Schneider, L., Mandl–Weber, S., Oduncu, F. S., & Schmidmaier, R. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834c8683 · Cited by 52
Prevention and management of mucositis in patients with cancer
Herrstedt, J. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00232-6 · Cited by 52
Where We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma
Bergsagel, P. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.199 · Cited by 52
Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma
Liu, K., Zhang, D., Chojnacki, J. E., Du, Y., Fu, H., Grant, S., & Zhang, S. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40595h · Cited by 52
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
D'Souza, C., Prince, H. M., & Neeson, P. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632399 · Cited by 52
Angiogenesis in multiple myeloma
Rajkumar, S. V. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90024-7 · Cited by 52
Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma
Alexanian, R., Weber, D., Anagnostopoulos, A., Delasalle, K. B., Wang, M. L., & Rankin, K. (2003) · Seminars in Hematology · doi:10.1053/j.seminhematol.2003.09.006 · Cited by 52
Clinical Translation of Targeted Protein Degraders
Kong, N. R., & Jones, L. H. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2985 · Cited by 54
Monoclonal antibodies — A new era in the treatment of multiple myeloma
Jelı́nek, T., & Hájek, R. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.08.004 · Cited by 50
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies
Sharma, R. A., Steward, W. P., Daines, C. A., Knight, R., O'Byrne, K. J., & Dalgleish, A. G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.018 · Cited by 51
Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65
Li, S., Xue, F., Cheng, Z., Yang, X., Wang, S., Geng, F., & Pan, L. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0409-z · Cited by 51
The molecular mechanism of thalidomide analogs in hematologic malignancies
Lindner, S., & Krönke, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1450-z · Cited by 51
Pharmacology of antineoplastic agents in older cancer patients
Lichtman, S. M., Skirvin, J. A., & Vemulapalli, S. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00120-8 · Cited by 51
Common and rare side‐effects of low‐dose thalidomide in multiple myeloma: focus on the dose‐minimizing peripheral neuropathy
Offidani, M., Corvatta, L., Marconi, M., Malerba, L., Mele, A., Olivieri, A., Brunori, M., Catarini, M., Candela, M., Capelli, D., et al. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00238.x · Cited by 51
Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans
Lu, J., Helsby, N. A., Palmer, B. D., Tingle, M. D., Baguley, B. C., Kestell, P., & Ching, L. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067793 · Cited by 51
Thalidomide therapy induces response in relapsed mantle cell lymphoma
Damaj, G. L., Lefrère, F., Delarue, R., Varet, B. R., Furman, R. R., & Hermine, O. (2003) · Leukemia · doi:10.1038/sj.leu.2403058 · Cited by 51
Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol
Semenov, I., Akyüz, C., Roginskaya, V. Y., Chauhan, D., & Corey, S. J. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00103-5 · Cited by 51
Irinotecan and thalidomide in metastatic colorectal cancer.
Govindarajan, R. (2000) · PubMed · Cited by 51
Thalidomide in the management of multiple myeloma
Barlogie, B. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90027-2 · Cited by 51
Self-citation
The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer
Los, M., & Voest, E. E. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90047-8 · Cited by 51
Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo
Valckenborgh, E. V., Raeve, H. D., Devy, L., Blacher, S., Munaut, C., Noël, A., Marck, E. V., Riet, I. V., Camp, B. V., & Vanderkerken, K. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600137 · Cited by 51
Evaluating Antiangiogenesis Agents in the Clinic
Sparano, J. A., Gray, R. J., Giantonio, B. J., O'Dwyer, P. J., & Comis, R. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0238 · Cited by 51
Pericytes as targets in hereditary hemorrhagic telangiectasia
Thalgott, J. H., Dos-Santos-Luis, D., & Lebrin, F. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00037 · Cited by 51
Clinical biomarkers of angiogenesis inhibition
Brown, A. P., Citrin, D. E., & Camphausen, K. A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9143-x · Cited by 49
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
Marriott, J. B., Clarke, I., Czajka, A., Dredge, K. S., Childs, K., Man, H., Schafer, P. H., Govinda, S., Muller, G. W., Stirling, D., et al. (2003) · PubMed · Cited by 50
Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors
Lepper, E. R., Ng, S. S. W., Gütschow, M., Weiss, M., Hauschildt, S., Hecker, T. K., Luzzio, F. A., Eger, K., & Figg, W. D. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0304820 · Cited by 50
Novel biological therapies for the treatment of multiple myeloma
Richardson, P. G. G., Mitsiades, C. S., Hideshima, T., & Anderson, K. C. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.010 · Cited by 50
Thalidomide: A novel template for anticancer drugs
Stirling, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90032-6 · Cited by 50
CD48 as a novel molecular target for antibody therapy in multiple myeloma
Hosen, N., Ichihara, H., Mugitani, A., Aoyama, Y., Fukuda, Y., Kishida, S., Matsuoka, Y., Nakajima, H., Kawakami, M., Yamagami, T., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08941.x · Cited by 51
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches
Engelhardt, M. M., Kleber, M., Udi, J., Wäsch, R., Spencer, A. G., Patriarca, F. F., Knop, S. T., Bruno, B., Gramatzki, M., Morabito, F., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.487959 · Cited by 49
Targeting Multiple Myeloma Cells and Their Bone Marrow Microenvironment
PAGNUCCO, G., Cardinale, G., & Gervasi, F. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1322.047 · Cited by 49
Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma
Grugan, K. D., Ma, C., Singhal, S., Krett, N. L., & Rosen, S. T. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.11.003 · Cited by 51
Self-citation
Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients
Kaya, H., Peressini, B., Jawed, I., Martincic, D., Elaimy, A. L., Lamoreaux, W. T., Fairbanks, R. K., Weeks, K. A., & Lee, C. M. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0971-z · Cited by 51
Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma
Cavo, M., Raimondo, F. D., Zamagni, E., Patriarca, F. F., Tacchetti, P., Casulli, A. F., Volpe, S., Perrone, G., Ledda, A., Ceccolini, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7389 · Cited by 50
Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Caraglia, M., Marra, M., Tagliaferri, P., Lamberts, S. W. J., Zappavigna, S., Misso, G., Cavagnini, F., Facchini, G., Abbruzzese, A., Hofland, L. J., et al. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789056980 · Cited by 49

Authors: Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., Siegel, D., Crowley, J., & Barlogie, B.
Affiliations: University of South Carolina (US)
University of Arkansas for Medical Sciences (US)
Rockefeller University (US)
ORCID: Singhal, Seema
Desikan, Raman
Roberson, Paula
Munshi, Nikhil
Dhodapkar, Madhav
Zeldis, Jerome
Siegel, David
Barlogie, Bart
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1999-11-18
Volume: 341
Issue: 21
Pages: 1565-1571
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199911183412102
OpenAlex: W2316160054
Cited by: 2,575
References: 35
Citations by year: 2026: 27 · 2025: 41 · 2024: 48 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 62 · 2019: 67 · 2018: 56 · 2017: 62 · 2016: 69 · 2015: 75 · 2014: 76 · 2013: 102 · 2012: 89
FWCI: 69.79
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P01CA055819, CA-55819)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords: thalidomide, multiple myeloma, refractory multiple myeloma, anti-angiogenic therapy, Bence Jones protein, microvessel density, event-free survival, overall survival, adverse effects
MeSH terms: Bence Jones Protein, Bone Marrow, Bone Marrow Examination, Drug Administration Schedule, Female, Humans, Male, Microcirculation, Middle Aged, Multiple Myeloma, Myeloma Proteins, Recurrence, Remission Induction, Thalidomide, Multivariate Analysis, Survival Analysis, Disease Progression, Angiogenesis Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks